Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025)

"patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits."
Michael DeMarco, PhD

by Michael DeMarco, PhD

Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness - PubMed
This is the first systematic review to assess the effectiveness of ketamine/esketamine in this cohort. Our findings suggest that ketamine/esketamine may be useful in improving symptoms of depression, in those with comorbid borderline personality disorder. Limited study data are available; however, g …
PubMedEmma Scott

More like this

Racemic Ketamine vs Esketamine in Treatment-Resistant Depression: The Overlooked Role of Arketamine (Tan, et al, 2025)

Evidence suggests that "IV racemic ketamine is more effective than IN esketamine in TRD; convergent preclinical and clinical findings support the hypothesis that arketamine plays a key role in this superiority and that ketamine’s antidepressant mechanisms extend beyond simple NMDAR antagonism."

The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews (Correa de Costa, et al, 2025)

"...evidence suggests that the use of serotonergic and non-serotonergic psychedelics (ketamine) for the treatment of SUD may provide advantages over traditional therapeutics, and these compounds may eventually become part of the next generation of treatments for SUD under specific circumstances."

Spotlight: A long, strange trip: Ketamine treatment in psychiatry (Nutt, et al, 2025)

"...mystical experiences were strongly related to immediate and sustained psychiatric benefits at the group level and on an individual, session-by-session basis across the six doses, providing mechanistic support for ketamine-psychotherapy pairings."

Spotlight: Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice (Serretti, 2025)

"Depression is increasingly conceptualized as a disorder of impaired synaptic plasticity and excitation-inhibition imbalance within corticolimbic circuits. Ketamine, brexanolone, zuranolone, offer complementary approaches to restore circuit function."

Spotlight: Personality profiles and trauma history in ketamine therapy for mood and anxiety disorders: A latent profile analysis of short-term outcomes (Gregoire, et al, 2025)

"Personality traits relate to baseline mental health severity but not short-term response to ketamine. Trauma history may predict greater benefit from treatment."

Spotlight: Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction (Palhas, et al, 2025)

"Serotonergic psychedelics & ketamine appear to share common cellular mechanisms. They both recruit glutamatergic neurons to stimulate BDNF-trKB signaling, promoting synaptogenesis via the mTOR pathway. These changes may explain their efficacy in depression, anxiety, PTSD, & addiction."
Mastodon Mastodon